Trials

OCT 23, 2026 · PHASE 1 TRIAL

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT07893106). This is a study registration, not published results. Lead sponsor: Ascletis Pharma (China) Co., Limited. Recruitment status:

OCT 23, 2026 · PHASE 2 TRIAL

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT04944706). This is a study registration, not published results. Lead sponsor: Tasly Pharmaceutical Group Co., Ltd. Recruitment status: C

OCT 23, 2026 · INTERVENTIONAL STUDY

Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT07482865). This is a study registration, not published results. Lead sponsor: Samsung Medical Center. Recruitment status: RECRUITING. Ph

OCT 23, 2026 · OBSERVATIONAL STUDY

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT07893223). This is a study registration, not published results. Lead sponsor: Nutromics. Recruitment status: NOT_YET_RECRUITING. Study t

OCT 23, 2026 · INTERVENTIONAL STUDY

A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT07893002). This is a study registration, not published results. Lead sponsor: Sichuan Credit Pharmaceutical Co., Ltd.. Recruitment statu

OCT 23, 2026 · PHASE 1/2 TRIAL

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT03581487). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: COMPLETED

OCT 23, 2026 · PHASE 3 TRIAL

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT02051218). This is a study registration, not published results. Lead sponsor: Swiss Cancer Institute. Recruitment status: TERMINATED. Ph

OCT 23, 2026 · PHASE 2 TRIAL

Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis

ClinicalTrials.gov

Registry record from ClinicalTrials.gov (NCT07892794). This is a study registration, not published results. Lead sponsor: Universitas Sebelas Maret. Recruitment status: COMPLETED.